Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Monopar TherapeuticsMNPR · Entity 5152 | Director | August 26, 2026 | August 29, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Monopar Therapeutics
Report date August 26, 2026 · Filed August 29, 2026 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Last balance in matching sequence
After 2026-08-26 transaction · row 8
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
8 source rowsRow 1 · 2026-08-26 · Exercise / conversion · Acquired 2,055 · Balance 2,055 F1: This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on May 27, 2026. Row 2 · 2026-08-26 · Exercise / conversion · Acquired 2,035 · Balance 4,090 F1: This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on May 27, 2026. Row 3 · 2026-08-26 · Sale · Disposed 485 · Balance 3,605 F1: This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on May 27, 2026. F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $108.07 to $109.05, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (4) through (9) to this Form 4. Row 4 · 2026-08-26 · Sale · Disposed 615 · Balance 2,990 F1: This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on May 27, 2026. F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $109.07 to $110.04, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (4) through (9) to this Form 4. Row 5 · 2026-08-26 · Sale · Disposed 700 · Balance 2,290 F1: This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on May 27, 2026. F6: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $110.14 to $111.05, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (4) through (9) to this Form 4. Row 6 · 2026-08-26 · Sale · Disposed 1,098 · Balance 1,192 F1: This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on May 27, 2026. F7: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $111.30 to $112.27, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (4) through (9) to this Form 4. Row 7 · 2026-08-26 · Sale · Disposed 602 · Balance 590 F1: This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on May 27, 2026. F8: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $112.30 to $113.25, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (4) through (9) to this Form 4. Row 8 · 2026-08-26 · Sale · Disposed 590 · Balance 0 F1: This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on May 27, 2026. F9: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $113.35 to $114.34, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (4) through (9) to this Form 4. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $30.00 · Expires 2028-08-27 | Direct | 6,165 |
Reported balance
After 2026-08-26 transaction · row 10
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 10 · 2026-08-26 · Exercise / conversion · Acquired 2,055 · Balance 6,165 F1: This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on May 27, 2026. F2: On August 28, 2018, the reporting person was granted stock options to purchase up to 8,220 shares of common stock. The options vest 6/51 on the six-month anniversary of vesting commencement date of October 1, 2018 and 1/51 per month thereafter. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $14.00 · Expires 2029-06-30 | Direct | 8,140 |
Reported balance
After 2026-08-26 transaction · row 11
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 11 · 2026-08-26 · Exercise / conversion · Acquired 2,035 · Balance 8,140 F1: This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on May 27, 2026. F3: On February 2, 2022, the reporting person was granted stock options to purchase up to 16,279 shares of common stock. The options vest 6/48ths on June 30, 2022 and 1/48ths per month thereafter. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 11,486 |
Reported balance
Holding disclosure · report date 2026-08-26 · row 9
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 9 · Balance 11,486 F10: Represents shares held by the Kim R. Tsuchimoto Trust dated October 6, 2015. |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on May 27, 2026.
F2: On August 28, 2018, the reporting person was granted stock options to purchase up to 8,220 shares of common stock. The options vest 6/51 on the six-month anniversary of vesting commencement date of October 1, 2018 and 1/51 per month thereafter.
F3: On February 2, 2022, the reporting person was granted stock options to purchase up to 16,279 shares of common stock. The options vest 6/48ths on June 30, 2022 and 1/48ths per month thereafter.
F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $108.07 to $109.05, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (4) through (9) to this Form 4.
F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $109.07 to $110.04, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (4) through (9) to this Form 4.
F6: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $110.14 to $111.05, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (4) through (9) to this Form 4.
F7: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $111.30 to $112.27, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (4) through (9) to this Form 4.
F8: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $112.30 to $113.25, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (4) through (9) to this Form 4.
F9: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $113.35 to $114.34, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (4) through (9) to this Form 4.
F10: Represents shares held by the Kim R. Tsuchimoto Trust dated October 6, 2015.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 26, 2026 Filed Aug 27, 2026 22:28 UTC | Monopar Therapeutics MNPR · Entity 5152 | SaleCommon Stock | 590 | $113.84 | $67,165.60 |
DisclosureSEC source: 0001437749-26-029116 · rdgdoc.xml · nonDerivative · entry 6 Tsuchimoto Kim R · CIK 0001333516 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,396 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on 05/27/2026. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $113.35 to $114.34, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) through (7) to this Form 4. Read SEC document |
| August 26, 2026 Filed Aug 27, 2026 22:28 UTC | Monopar Therapeutics MNPR · Entity 5152 | SaleCommon Stock | 602 | $112.93 | $67,983.86 |
DisclosureSEC source: 0001437749-26-029116 · rdgdoc.xml · nonDerivative · entry 5 Tsuchimoto Kim R · CIK 0001333516 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,986 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on 05/27/2026. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $112.30 to $113.25, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) through (7) to this Form 4. Read SEC document |
| August 26, 2026 Filed Aug 27, 2026 22:28 UTC | Monopar Therapeutics MNPR · Entity 5152 | SaleCommon Stock | 1,098 | $111.84 | $122,800.32 |
DisclosureSEC source: 0001437749-26-029116 · rdgdoc.xml · nonDerivative · entry 4 Tsuchimoto Kim R · CIK 0001333516 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,588 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on 05/27/2026. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $111.30 to $112.27, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) through (7) to this Form 4. Read SEC document |
| August 26, 2026 Filed Aug 27, 2026 22:28 UTC | Monopar Therapeutics MNPR · Entity 5152 | SaleCommon Stock | 700 | $110.65 | $77,455.00 |
DisclosureSEC source: 0001437749-26-029116 · rdgdoc.xml · nonDerivative · entry 3 Tsuchimoto Kim R · CIK 0001333516 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,686 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on 05/27/2026. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $110.14 to $111.05, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) through (7) to this Form 4. Read SEC document |
| August 26, 2026 Filed Aug 27, 2026 22:28 UTC | Monopar Therapeutics MNPR · Entity 5152 | SaleCommon Stock | 615 | $109.56 | $67,379.40 |
DisclosureSEC source: 0001437749-26-029116 · rdgdoc.xml · nonDerivative · entry 2 Tsuchimoto Kim R · CIK 0001333516 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,386 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on 05/27/2026. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $109.07 to $110.04, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) through (7) to this Form 4. Read SEC document |
| August 26, 2026 Filed Aug 27, 2026 22:28 UTC | Monopar Therapeutics MNPR · Entity 5152 | SaleCommon Stock | 485 | $108.83 | $52,782.55 |
DisclosureSEC source: 0001437749-26-029116 · rdgdoc.xml · nonDerivative · entry 1 Tsuchimoto Kim R · CIK 0001333516 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 11,001 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on 05/27/2026. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $108.07 to $109.05, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) through (7) to this Form 4. Read SEC document |
| August 26, 2026 Filed Aug 29, 2026 00:18 UTC Amendment | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionStock Option · Derivative | 2,035 | $0.00 Strike: $14.00 | $0.00 |
DisclosureSEC source: 0001437749-26-029235 · rdgdoc.xml · derivative · entry 11 Tsuchimoto Kim R · CIK 0001333516 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,140 Underlying: Common Stock · 2,035 shares Expires 2029-06-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on May 27, 2026. F3 · derivative.exercise_date: On February 2, 2022, the reporting person was granted stock options to purchase up to 16,279 shares of common stock. The options vest 6/48ths on June 30, 2022 and 1/48ths per month thereafter. Read SEC document |
| August 26, 2026 Filed Aug 29, 2026 00:18 UTC Amendment | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionStock Option · Derivative | 2,055 | $0.00 Strike: $30.00 | $0.00 |
DisclosureSEC source: 0001437749-26-029235 · rdgdoc.xml · derivative · entry 10 Tsuchimoto Kim R · CIK 0001333516 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,165 Underlying: Common Stock · 2,055 shares Expires 2028-08-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on May 27, 2026. F2 · derivative.exercise_date: On August 28, 2018, the reporting person was granted stock options to purchase up to 8,220 shares of common stock. The options vest 6/51 on the six-month anniversary of vesting commencement date of October 1, 2018 and 1/51 per month thereafter. Read SEC document |
| August 26, 2026 Filed Aug 29, 2026 00:18 UTC Amendment | Monopar Therapeutics MNPR · Entity 5152 | SaleCommon Stock | 590 | $113.84 | $67,165.60 |
DisclosureSEC source: 0001437749-26-029235 · rdgdoc.xml · nonDerivative · entry 8 Tsuchimoto Kim R · CIK 0001333516 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on May 27, 2026. F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $113.35 to $114.34, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (4) through (9) to this Form 4. Read SEC document |
| August 26, 2026 Filed Aug 29, 2026 00:18 UTC Amendment | Monopar Therapeutics MNPR · Entity 5152 | SaleCommon Stock | 602 | $112.93 | $67,983.86 |
DisclosureSEC source: 0001437749-26-029235 · rdgdoc.xml · nonDerivative · entry 7 Tsuchimoto Kim R · CIK 0001333516 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 590 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on May 27, 2026. F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $112.30 to $113.25, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (4) through (9) to this Form 4. Read SEC document |
| August 26, 2026 Filed Aug 29, 2026 00:18 UTC Amendment | Monopar Therapeutics MNPR · Entity 5152 | SaleCommon Stock | 1,098 | $111.84 | $122,800.32 |
DisclosureSEC source: 0001437749-26-029235 · rdgdoc.xml · nonDerivative · entry 6 Tsuchimoto Kim R · CIK 0001333516 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,192 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on May 27, 2026. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $111.30 to $112.27, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (4) through (9) to this Form 4. Read SEC document |
| August 26, 2026 Filed Aug 29, 2026 00:18 UTC Amendment | Monopar Therapeutics MNPR · Entity 5152 | SaleCommon Stock | 700 | $110.65 | $77,455.00 |
DisclosureSEC source: 0001437749-26-029235 · rdgdoc.xml · nonDerivative · entry 5 Tsuchimoto Kim R · CIK 0001333516 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,290 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on May 27, 2026. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $110.14 to $111.05, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (4) through (9) to this Form 4. Read SEC document |
| August 26, 2026 Filed Aug 29, 2026 00:18 UTC Amendment | Monopar Therapeutics MNPR · Entity 5152 | SaleCommon Stock | 615 | $109.56 | $67,379.40 |
DisclosureSEC source: 0001437749-26-029235 · rdgdoc.xml · nonDerivative · entry 4 Tsuchimoto Kim R · CIK 0001333516 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,990 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on May 27, 2026. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $109.07 to $110.04, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (4) through (9) to this Form 4. Read SEC document |
| August 26, 2026 Filed Aug 29, 2026 00:18 UTC Amendment | Monopar Therapeutics MNPR · Entity 5152 | SaleCommon Stock | 485 | $108.83 | $52,782.55 |
DisclosureSEC source: 0001437749-26-029235 · rdgdoc.xml · nonDerivative · entry 3 Tsuchimoto Kim R · CIK 0001333516 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,605 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on May 27, 2026. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $108.07 to $109.05, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (4) through (9) to this Form 4. Read SEC document |
| August 26, 2026 Filed Aug 29, 2026 00:18 UTC Amendment | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionCommon Stock | 2,035 | $14.00 | $28,490.00 |
DisclosureSEC source: 0001437749-26-029235 · rdgdoc.xml · nonDerivative · entry 2 Tsuchimoto Kim R · CIK 0001333516 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,090 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on May 27, 2026. Read SEC document |
| August 26, 2026 Filed Aug 29, 2026 00:18 UTC Amendment | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionCommon Stock | 2,055 | $30.00 | $61,650.00 |
DisclosureSEC source: 0001437749-26-029235 · rdgdoc.xml · nonDerivative · entry 1 Tsuchimoto Kim R · CIK 0001333516 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,055 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on May 27, 2026. Read SEC document |
| December 02, 2025 Filed Dec 8, 2025 21:47 UTC | Monopar Therapeutics MNPR · Entity 5152 | GrantStock Options · Derivative | 2,924 | $0.00 Strike: $75.94 | $0.00 |
DisclosureSEC source: 0001437749-25-037165 · rdgdoc.xml · derivative · entry 1 Tsuchimoto Kim R · CIK 0001333516 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,924 Underlying: Common Stock · 2,924 shares Expires 2035-12-02 F1 · derivative.exercise_date: Options vest 25% quarterly on March 31, 2026, June 30, 2026, September 30, 2026 and December 31, 2026. Read SEC document |
| July 14, 2025 Filed Jul 17, 2025 01:06 UTC | Monopar Therapeutics MNPR · Entity 5152 | OtherStock Options · Derivative | 4,704 | $0.00 Strike: $0.01 | $0.00 |
DisclosureSEC source: 0001437749-25-022863 · rdgdoc.xml · derivative · entry 4 Tsuchimoto Kim R · CIK 0001333516 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,704 shares Expires 2027-02-20 F4 · derivative.exercise_date: Reflects options to purchase a total of 4,704 shares of common stock granted to Ms. Tsuchimoto on February 20, 2017, for her services as a director and prior officer of Monopar Therapeutics. The options vested 6/48ths upon the 6-month anniversary of the grant date and 1/48th per month thereafter. Read SEC document |
| July 14, 2025 Filed Jul 17, 2025 01:06 UTC | Monopar Therapeutics MNPR · Entity 5152 | OtherStock Options · Derivative | 4,200 | $0.00 Strike: $0.01 | $0.00 |
DisclosureSEC source: 0001437749-25-022863 · rdgdoc.xml · derivative · entry 3 Tsuchimoto Kim R · CIK 0001333516 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,200 shares Expires 2026-04-04 F3 · derivative.exercise_date: Reflects options to purchase a total of 4,200 shares of common stock granted to Ms. Tsuchimoto on April 4, 2016, for her services as a director and prior officer of Monopar Therapeutics.The options vested 6/12ths upon the grant date and 3/12th every 6 months thereafter. Read SEC document |
| July 14, 2025 Filed Jul 17, 2025 01:06 UTC | Monopar Therapeutics MNPR · Entity 5152 | SaleCommon Stock | 8,904 | $40.00 | $356,170.68 |
DisclosureSEC source: 0001437749-25-022863 · rdgdoc.xml · nonDerivative · entry 2 Tsuchimoto Kim R · CIK 0001333516 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,486 F2 · price: The shares were sold in multiple transactions at prices ranging from $40.00 to $40.25, inclusive. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| July 14, 2025 Filed Jul 17, 2025 01:06 UTC | Monopar Therapeutics MNPR · Entity 5152 | OtherCommon Stock | 8,904 | $0.01 | $44.52 |
DisclosureSEC source: 0001437749-25-022863 · rdgdoc.xml · nonDerivative · entry 1 Tsuchimoto Kim R · CIK 0001333516 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,390 F1 · shares: This transaction involved a cash exercise of stock options. Read SEC document |
| March 04, 2025 Filed Mar 8, 2025 00:48 UTC | Monopar Therapeutics MNPR · Entity 5152 | GrantStock Options · Derivative | 11,365 | $0.00 Strike: $31.70 | $0.00 |
DisclosureSEC source: 0001437749-25-006723 · rdgdoc.xml · derivative · entry 1 Tsuchimoto Kim R · CIK 0001333516 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,365 Underlying: Common Stock · 11,365 shares Expires 2035-03-04 F1 · derivative.exercise_date: Options vest 25% quarterly on March 31, 2025, June 30, 2025, September 30, 2025 and December 31, 2025. Read SEC document |
| June 30, 2024 Filed Jul 2, 2024 22:08 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionRestricted Stock Units · Derivative | 9,957 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-24-022024 · rdgdoc.xml · derivative · entry 3 Tsuchimoto Kim R · CIK 0001333516 · Director · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 74,412 Underlying: Common Stock · 9,957 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Represents shares acquired on vesting and settlement of restricted stock units. F3 · derivative.exercise_date: On January 26, 2021, the reporting person was granted 19,536 restricted stock units, vesting 6/48ths (2,442 shares) on June 30, 2021, and 3/48ths (1,221 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2024. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F4 · derivative.exercise_date: On February 2, 2022, the reporting person was granted 61,532 restricted stock units, vesting 6/48ths (7,692 shares) on June 30, 2022, and 3/48ths (3,846 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F5 · derivative.exercise_date: On February 1, 2023, the reporting person was granted 78,234 restricted stock units, vesting 6/48ths (9,779 shares) on June 30, 2023, and 3/48ths (4,890 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2026. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F3 · derivative.expiration_date: On January 26, 2021, the reporting person was granted 19,536 restricted stock units, vesting 6/48ths (2,442 shares) on June 30, 2021, and 3/48ths (1,221 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2024. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F4 · derivative.expiration_date: On February 2, 2022, the reporting person was granted 61,532 restricted stock units, vesting 6/48ths (7,692 shares) on June 30, 2022, and 3/48ths (3,846 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F5 · derivative.expiration_date: On February 1, 2023, the reporting person was granted 78,234 restricted stock units, vesting 6/48ths (9,779 shares) on June 30, 2023, and 3/48ths (4,890 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2026. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. Read SEC document |
| June 30, 2024 Filed Jul 2, 2024 22:08 UTC | Monopar Therapeutics MNPR · Entity 5152 | Tax withholdingCommon Stock | 2,998 | $0.73 | $2,191.54 |
DisclosureSEC source: 0001437749-24-022024 · rdgdoc.xml · nonDerivative · entry 2 Tsuchimoto Kim R · CIK 0001333516 · Director · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 57,429 F2 · shares: Represents shares withheld by the issuer to pay for the applicable withholding tax due upon vesting of restricted stock units. Read SEC document |
| June 30, 2024 Filed Jul 2, 2024 22:08 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionCommon Stock | 9,957 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-24-022024 · rdgdoc.xml · nonDerivative · entry 1 Tsuchimoto Kim R · CIK 0001333516 · Director · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,427 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Represents shares acquired on vesting and settlement of restricted stock units. Read SEC document |
| March 31, 2024 Filed Apr 3, 2024 00:33 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionRestricted Stock Units · Derivative | 9,956 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-24-010722 · rdgdoc.xml · derivative · entry 3 Tsuchimoto Kim R · CIK 0001333516 · Director · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 84,369 Underlying: Common Stock · 9,956 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Represents shares acquired on vesting and settlement of restricted stock units. F3 · derivative.exercise_date: On January 26, 2021, the reporting person was granted 19,536 restricted stock units, vesting 6/48ths (2,442 shares) on June 30, 2021, and 3/48ths (1,221 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2024. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F4 · derivative.exercise_date: On February 2, 2022, the reporting person was granted 61,532 restricted stock units, vesting 6/48ths (7,692 shares) on June 30, 2022, and 3/48ths (3,846 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F5 · derivative.exercise_date: On February 1, 2023, the reporting person was granted 78,234 restricted stock units, vesting 6/48ths (9,779 shares) on June 30, 2023, and 3/48ths (4,890 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2026. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F3 · derivative.expiration_date: On January 26, 2021, the reporting person was granted 19,536 restricted stock units, vesting 6/48ths (2,442 shares) on June 30, 2021, and 3/48ths (1,221 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2024. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F4 · derivative.expiration_date: On February 2, 2022, the reporting person was granted 61,532 restricted stock units, vesting 6/48ths (7,692 shares) on June 30, 2022, and 3/48ths (3,846 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F5 · derivative.expiration_date: On February 1, 2023, the reporting person was granted 78,234 restricted stock units, vesting 6/48ths (9,779 shares) on June 30, 2023, and 3/48ths (4,890 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2026. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. Read SEC document |
| March 31, 2024 Filed Apr 3, 2024 00:33 UTC | Monopar Therapeutics MNPR · Entity 5152 | Tax withholdingCommon Stock | 4,082 | $0.68 | $2,779.84 |
DisclosureSEC source: 0001437749-24-010722 · rdgdoc.xml · nonDerivative · entry 2 Tsuchimoto Kim R · CIK 0001333516 · Director · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,470 F2 · shares: Represents shares withheld by the issuer to pay for the applicable withholding tax due upon vesting of restricted stock units. Read SEC document |
| March 31, 2024 Filed Apr 3, 2024 00:33 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionCommon Stock | 9,956 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-24-010722 · rdgdoc.xml · nonDerivative · entry 1 Tsuchimoto Kim R · CIK 0001333516 · Director · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,552 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Represents shares acquired on vesting and settlement of restricted stock units. Read SEC document |
| January 01, 2024 Filed Jan 4, 2024 00:34 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionRestricted Stock Units · Derivative | 1,231 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-24-000480 · rdgdoc.xml · derivative · entry 6 Tsuchimoto Kim R · CIK 0001333516 · Director · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 94,325 Underlying: Common Stock · 1,231 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Represents shares acquired on vesting and settlement of restricted stock units. F6 · derivative.exercise_date: On January 31, 2020 the reporting person was granted 4,923 restricted stock units, vesting in four equal annual installments with vesting dates on January 1, 2021, January 1, 2022, January 1, 2023, and January 1, 2024. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F6 · derivative.expiration_date: On January 31, 2020 the reporting person was granted 4,923 restricted stock units, vesting in four equal annual installments with vesting dates on January 1, 2021, January 1, 2022, January 1, 2023, and January 1, 2024. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. Read SEC document |
| January 01, 2024 Filed Jan 4, 2024 00:34 UTC | Monopar Therapeutics MNPR · Entity 5152 | Tax withholdingCommon Stock | 505 | $0.34 | $171.80 |
DisclosureSEC source: 0001437749-24-000480 · rdgdoc.xml · nonDerivative · entry 4 Tsuchimoto Kim R · CIK 0001333516 · Director · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,596 F2 · shares: Represents shares withheld by the issuer to pay for the applicable withholding tax due upon vesting of restricted stock units. Read SEC document |
| January 01, 2024 Filed Jan 4, 2024 00:34 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionCommon Stock | 1,231 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-24-000480 · rdgdoc.xml · nonDerivative · entry 3 Tsuchimoto Kim R · CIK 0001333516 · Director · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,101 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Represents shares acquired on vesting and settlement of restricted stock units. Read SEC document |
| December 31, 2023 Filed Jan 4, 2024 00:34 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionRestricted Stock Units · Derivative | 9,957 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-24-000480 · rdgdoc.xml · derivative · entry 5 Tsuchimoto Kim R · CIK 0001333516 · Director · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 95,556 Underlying: Common Stock · 9,957 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Represents shares acquired on vesting and settlement of restricted stock units. F3 · derivative.exercise_date: On January 26, 2021, the reporting person was granted 19,536 restricted stock units, vesting 6/48ths (2,442 shares) on June 30, 2021, and 3/48ths (1,221 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2024. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F4 · derivative.exercise_date: On February 2, 2022, the reporting person was granted 61,532 restricted stock units, vesting 6/48ths (7,692 shares) on June 30, 2022, and 3/48ths (3,846 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F5 · derivative.exercise_date: On February 1, 2023, the reporting person was granted 78,234 restricted stock units, vesting 6/48ths (9,779 shares) on June 30, 2023, and 3/48ths (4,890 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2026. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F3 · derivative.expiration_date: On January 26, 2021, the reporting person was granted 19,536 restricted stock units, vesting 6/48ths (2,442 shares) on June 30, 2021, and 3/48ths (1,221 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2024. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F4 · derivative.expiration_date: On February 2, 2022, the reporting person was granted 61,532 restricted stock units, vesting 6/48ths (7,692 shares) on June 30, 2022, and 3/48ths (3,846 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F5 · derivative.expiration_date: On February 1, 2023, the reporting person was granted 78,234 restricted stock units, vesting 6/48ths (9,779 shares) on June 30, 2023, and 3/48ths (4,890 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2026. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. Read SEC document |
| December 31, 2023 Filed Jan 4, 2024 00:34 UTC | Monopar Therapeutics MNPR · Entity 5152 | Tax withholdingCommon Stock | 4,073 | $0.34 | $1,385.63 |
DisclosureSEC source: 0001437749-24-000480 · rdgdoc.xml · nonDerivative · entry 2 Tsuchimoto Kim R · CIK 0001333516 · Director · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,870 F2 · shares: Represents shares withheld by the issuer to pay for the applicable withholding tax due upon vesting of restricted stock units. Read SEC document |
| December 31, 2023 Filed Jan 4, 2024 00:34 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionCommon Stock | 9,957 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-24-000480 · rdgdoc.xml · nonDerivative · entry 1 Tsuchimoto Kim R · CIK 0001333516 · Director · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,943 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Represents shares acquired on vesting and settlement of restricted stock units. Read SEC document |
| September 30, 2023 Filed Oct 3, 2023 23:36 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionRestricted Stock Units · Derivative | 9,956 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-23-027587 · rdgdoc.xml · derivative · entry 3 Tsuchimoto Kim R · CIK 0001333516 · Director · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 105,513 Underlying: Common Stock · 9,956 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Represents shares acquired on vesting and settlement of restricted stock units. F2 · derivative.exercise_date: On January 26, 2021, the reporting person was granted 19,536 restricted stock units, vesting 6/48ths (2,442 shares) on June 30, 2021, and 3/48ths (1,221 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2024. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F3 · derivative.exercise_date: On February 2, 2022, the reporting person was granted 61,532 restricted stock units, vesting 6/48ths (7,692 shares) on June 30, 2022, and 3/48ths (3,846 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F5 · derivative.exercise_date: On February 1, 2023, the reporting person was granted 78,234 restricted stock units, vesting 6/48ths (9,779 shares) on June 30, 2023, and 3/48ths (4,890 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2026. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F2 · derivative.expiration_date: On January 26, 2021, the reporting person was granted 19,536 restricted stock units, vesting 6/48ths (2,442 shares) on June 30, 2021, and 3/48ths (1,221 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2024. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F3 · derivative.expiration_date: On February 2, 2022, the reporting person was granted 61,532 restricted stock units, vesting 6/48ths (7,692 shares) on June 30, 2022, and 3/48ths (3,846 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F5 · derivative.expiration_date: On February 1, 2023, the reporting person was granted 78,234 restricted stock units, vesting 6/48ths (9,779 shares) on June 30, 2023, and 3/48ths (4,890 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2026. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. Read SEC document |
| September 30, 2023 Filed Oct 3, 2023 23:36 UTC | Monopar Therapeutics MNPR · Entity 5152 | Tax withholdingCommon Stock | 3,444 | $0.62 | $2,134.94 |
DisclosureSEC source: 0001437749-23-027587 · rdgdoc.xml · nonDerivative · entry 2 Tsuchimoto Kim R · CIK 0001333516 · Director · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,986 F4 · shares: Represents shares withheld by the issuer to pay for the applicable withholding tax due upon vesting of restricted stock units. Read SEC document |
| September 30, 2023 Filed Oct 3, 2023 23:36 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionCommon Stock | 9,956 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-23-027587 · rdgdoc.xml · nonDerivative · entry 1 Tsuchimoto Kim R · CIK 0001333516 · Director · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,430 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Represents shares acquired on vesting and settlement of restricted stock units. Read SEC document |
| June 30, 2023 Filed Jul 3, 2023 22:46 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionRestricted Stock Units · Derivative | 14,846 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-23-019258 · rdgdoc.xml · derivative · entry 3 Tsuchimoto Kim R · CIK 0001333516 · Director · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 115,469 Underlying: Common Stock · 14,846 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Represents shares acquired on vesting and settlement of restricted stock units. F2 · derivative.exercise_date: On January 26, 2021, the reporting person was granted 19,536 restricted stock units, vesting 6/48ths (2,442 shares) on June 30, 2021, and 3/48ths (1,221 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2024. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F3 · derivative.exercise_date: On February 2, 2022, the reporting person was granted 61,532 restricted stock units, vesting 6/48ths (7,692 shares) on June 30, 2022, and 3/48ths (3,846 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F5 · derivative.exercise_date: On February 1, 2023, the reporting person was granted 78,234 restricted stock units, vesting 6/48ths (9,779 shares) on June 30, 2023, and 3/48ths (4,889 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2026. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F2 · derivative.expiration_date: On January 26, 2021, the reporting person was granted 19,536 restricted stock units, vesting 6/48ths (2,442 shares) on June 30, 2021, and 3/48ths (1,221 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2024. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F3 · derivative.expiration_date: On February 2, 2022, the reporting person was granted 61,532 restricted stock units, vesting 6/48ths (7,692 shares) on June 30, 2022, and 3/48ths (3,846 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F5 · derivative.expiration_date: On February 1, 2023, the reporting person was granted 78,234 restricted stock units, vesting 6/48ths (9,779 shares) on June 30, 2023, and 3/48ths (4,889 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2026. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. Read SEC document |
| June 30, 2023 Filed Jul 3, 2023 22:46 UTC | Monopar Therapeutics MNPR · Entity 5152 | Tax withholdingCommon Stock | 5,104 | $0.86 | $4,363.92 |
DisclosureSEC source: 0001437749-23-019258 · rdgdoc.xml · nonDerivative · entry 2 Tsuchimoto Kim R · CIK 0001333516 · Director · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,474 F4 · shares: Represents shares withheld by the issuer to pay for the applicable withholding tax due upon vesting of restricted stock units. Read SEC document |
| June 30, 2023 Filed Jul 3, 2023 22:46 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionCommon Stock | 14,846 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-23-019258 · rdgdoc.xml · nonDerivative · entry 1 Tsuchimoto Kim R · CIK 0001333516 · Director · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,578 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Represents shares acquired on vesting and settlement of restricted stock units. Read SEC document |
| March 31, 2023 Filed Apr 4, 2023 21:16 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionRestricted Stock Units · Derivative | 5,067 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-23-009331 · rdgdoc.xml · derivative · entry 3 Tsuchimoto Kim R · CIK 0001333516 · Director · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 130,315 Underlying: Common Stock · 5,067 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Represents shares acquired on vesting and settlement of restricted stock units. F2 · derivative.exercise_date: On January 26, 2021, the reporting person was granted 19,536 restricted stock units, vesting 6/48ths (2,442 shares) on June 30, 2021, and 3/48ths (1,221 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2024. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F3 · derivative.exercise_date: On February 2, 2022, the reporting person was granted 61,532 restricted stock units, vesting 6/48ths (7,692 shares) on June 30, 2022, and 3/48ths (3,846 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F2 · derivative.expiration_date: On January 26, 2021, the reporting person was granted 19,536 restricted stock units, vesting 6/48ths (2,442 shares) on June 30, 2021, and 3/48ths (1,221 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2024. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F3 · derivative.expiration_date: On February 2, 2022, the reporting person was granted 61,532 restricted stock units, vesting 6/48ths (7,692 shares) on June 30, 2022, and 3/48ths (3,846 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. Read SEC document |
| March 31, 2023 Filed Apr 4, 2023 21:16 UTC | Monopar Therapeutics MNPR · Entity 5152 | Tax withholdingCommon Stock | 1,842 | $1.39 | $2,560.38 |
DisclosureSEC source: 0001437749-23-009331 · rdgdoc.xml · nonDerivative · entry 2 Tsuchimoto Kim R · CIK 0001333516 · Director · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,732 F4 · shares: Represents shares withheld by the issuer to pay for the applicable withholding tax due upon vesting of restricted stock units. Read SEC document |
| March 31, 2023 Filed Apr 4, 2023 21:16 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionCommon Stock | 5,067 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-23-009331 · rdgdoc.xml · nonDerivative · entry 1 Tsuchimoto Kim R · CIK 0001333516 · Director · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,574 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Represents shares acquired on vesting and settlement of restricted stock units. Read SEC document |
| February 01, 2023 Filed Feb 3, 2023 23:45 UTC | Monopar Therapeutics MNPR · Entity 5152 | GrantRestricted Stock Units · Derivative | 78,234 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001437749-23-002516 · rdgdoc.xml · derivative · entry 2 Tsuchimoto Kim R · CIK 0001333516 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,382 Underlying: Common Stock · 78,234 shares Expires not disclosed F2 · derivative.exercise_date: RSUs vest 6/48ths on June 30, 2023 and 3/48ths per quarter thereafter (September 30, 2023, December 31, 2023, March 31, 2024, June 30, 2024, September 30, 2024, December 31, 2024, March 31, 2025, June 30, 2025, September 30, 2025, December 31, 2025, March 31, 2026, June 30, 2026, September 30, 2026, December 31, 2026) F2 · derivative.expiration_date: RSUs vest 6/48ths on June 30, 2023 and 3/48ths per quarter thereafter (September 30, 2023, December 31, 2023, March 31, 2024, June 30, 2024, September 30, 2024, December 31, 2024, March 31, 2025, June 30, 2025, September 30, 2025, December 31, 2025, March 31, 2026, June 30, 2026, September 30, 2026, December 31, 2026) Read SEC document |
| February 01, 2023 Filed Feb 3, 2023 23:45 UTC | Monopar Therapeutics MNPR · Entity 5152 | GrantStock Options · Derivative | 102,688 | $0.00 Strike: $3.16 | $0.00 |
DisclosureSEC source: 0001437749-23-002516 · rdgdoc.xml · derivative · entry 1 Tsuchimoto Kim R · CIK 0001333516 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,688 Underlying: Common Stock · 102,688 shares Expires 2033-02-01 F1 · derivative.exercise_date: Options vest 6/48ths on June 30, 2023 and 1/48th per month thereafter. Read SEC document |
| January 01, 2023 Filed Jan 3, 2023 21:03 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionRestricted Stock Units · Derivative | 1,230 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-23-000166 · rdgdoc.xml · derivative · entry 6 Tsuchimoto Kim R · CIK 0001333516 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,231 Underlying: Common Stock · 1,230 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Represents shares acquired on vesting and settlement of restricted stock units. F4 · derivative.exercise_date: On January 31, 2020, the reporting person was granted 4,923 restricted stock units, vesting in four equal annual installments with vesting dates on January 1, 2021, January 1, 2022, January 1, 2023, and January 1, 2024. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F4 · derivative.expiration_date: On January 31, 2020, the reporting person was granted 4,923 restricted stock units, vesting in four equal annual installments with vesting dates on January 1, 2021, January 1, 2022, January 1, 2023, and January 1, 2024. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. Read SEC document |
| January 01, 2023 Filed Jan 3, 2023 21:03 UTC | Monopar Therapeutics MNPR · Entity 5152 | Tax withholdingCommon Stock | 502 | $2.37 | $1,189.74 |
DisclosureSEC source: 0001437749-23-000166 · rdgdoc.xml · nonDerivative · entry 4 Tsuchimoto Kim R · CIK 0001333516 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,507 Read SEC document |
| January 01, 2023 Filed Jan 3, 2023 21:03 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionCommon Stock | 1,230 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-23-000166 · rdgdoc.xml · nonDerivative · entry 3 Tsuchimoto Kim R · CIK 0001333516 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,009 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Represents shares acquired on vesting and settlement of restricted stock units. Read SEC document |
| December 31, 2022 Filed Jan 3, 2023 21:03 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionRestricted Stock Units · Derivative | 5,067 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-23-000166 · rdgdoc.xml · derivative · entry 5 Tsuchimoto Kim R · CIK 0001333516 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,917 Underlying: Common Stock · 5,067 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Represents shares acquired on vesting and settlement of restricted stock units. F2 · derivative.exercise_date: On January 26, 2021, the reporting person was granted 19,536 restricted stock units, vesting 6/48ths (2,442 shares) on June 30, 2021, and 3/48ths (1,221 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2024. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F3 · derivative.exercise_date: On February 2, 2022, the reporting person was granted 61,532 restricted stock units, vesting 6/48ths (7,692 shares) on June 30, 2022, and 3/48ths (3,846 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F2 · derivative.expiration_date: On January 26, 2021, the reporting person was granted 19,536 restricted stock units, vesting 6/48ths (2,442 shares) on June 30, 2021, and 3/48ths (1,221 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2024. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F3 · derivative.expiration_date: On February 2, 2022, the reporting person was granted 61,532 restricted stock units, vesting 6/48ths (7,692 shares) on June 30, 2022, and 3/48ths (3,846 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. Read SEC document |
| December 31, 2022 Filed Jan 3, 2023 21:03 UTC | Monopar Therapeutics MNPR · Entity 5152 | Tax withholdingCommon Stock | 2,067 | $2.37 | $4,898.79 |
DisclosureSEC source: 0001437749-23-000166 · rdgdoc.xml · nonDerivative · entry 2 Tsuchimoto Kim R · CIK 0001333516 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,779 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.